247 Users Online
Osteoporosis Drugs Market Segmented By Bisphosphonates, Parathyroid Hormone Therapy Drugs, Calcitonin, Selective Estrogen Receptors Modulators, RANK Ligand Inhibitors Drugs Type
The global revenue from the osteoporosis drugs market stands at US$ 13.0 Bn in 2022, with the global market expected to grow at a CAGR of 3.5% to reach a valuation of approximately US$ 18.9 Bn by the end of 2033.
Market Size (2022)
US$ 13.0 Bn
Projected Market Value (2033)
US$ 18.9 Bn
Global Market Growth Rate (2023-2033)
Market Share of Top 4 Countries
As assessed by Persistence Market Research, bisphosphonates will hold a market share of around 43.6% in 2023. Overall, osteoporosis drugs market sales account for approximately 24.1% revenue share in the global orthopedic drugs and devices market, which was valued at around US$ 53.9 Bn in 2022.
The global market recorded a historic CAGR of 2.7% in the last 6 years from 2016 to 2022.
Osteoporosis is a bone disease that affects millions of people worldwide and raises the risk of fracture due to poor bone mineral density and degeneration of bone architecture. There have been 10 million men and women identified with osteoporosis in the US alone, and this figure is continuing to rise. Bone mineral density measurements are used to make diagnoses.
The drugs bisphosphonates, denosumab, raloxifene, and teriparatide are used to treat osteoporosis. Romosozumab was also recently introduced in the market for the treatment of osteoporosis.
Numerous improvements have been made in the various osteoporosis therapy choices and diagnostic techniques in recent years. Sizable portions of people are receiving inadequate or no treatment for osteoporosis despite these advancements and the rising incidence of the disease.
As per a retrospective analysis using the Premier Perspective Database (2010 − 2013), hip fractures, which make up 50% of osteoporotic fracture-related hospitalisations, are among the fractures that necessitate hospitalisation.
The high prevalence of osteoporosis places a significant strain on our society's ability to maintain good public health. It is linked to an increased risk of fragility fractures. The morbidity of all osteoporotic fractures increases and the mortality of fractures of the hip and vertebrae consequently rises.
According to the International Osteoporosis Foundation (IOF), fragility fractures resulted in an estimated 1 million quality-adjusted life years (QALYs) to be lost in six European countries in 2017. In the remaining years of their lives, one in five men and one in two women who are 50 years old will suffer an osteoporotic fracture.
Low bone density and degeneration of bone architecture are the hallmarks of osteoporosis, which raises the risk of fractures. Bone mineral density (BMD) is typically measured for the diagnosis of osteoporosis utilising non-invasive dual-energy X-ray absorptiometry.
Effective medicines for treating osteoporosis have been developed as a result of recent developments in drug development over the past three decades. However, osteoporosis is severely undertreated. Osteoporosis treatment gaps are growing as a result of concerns about rare adverse effects, persistent comorbidities, and the short-term efficacy of anti-resorptive drugs. Numerous international health groups, including the Gerontological Society of America, the ASBMR, and the Fragility Fracture Network, have made calls for a global response to the treatment gap.
Thus, owed to the above-mentioned factors, the global market is likely to show high growth over the coming years at a CAGR of 3.5% and reach a global market valuation of US$ 18.9 Bn by 2033.
“Development of Novel Therapeutic Modality and Association of Skin Disorders with the Development of Osteoporosis”
In an ageing or old society, osteoporosis is an unavoidable public health issue. Anti-resorptive and anabolic drugs play important roles in current treatment regimens, and they can be administered alone or in combination depending on the pathological conditions.
Recent advances in the molecular comprehension of bone metabolism and bioengineering will pave the way for future osteoporosis treatment paradigms such as antibody therapeutics, stem cell therapies, and gene therapies.
Furthermore, skin disorders are the fourth leading cause of death around the globe, affecting around one-third of the global population and being more common in frequency among elderly males. Inflammation and the many accompanying cytokine patterns are at the root of both osteoporosis and the majority of skin disorders. Furthermore, dermatological patients may be subjected to local or systemic treatments containing glucocorticoids and immunosuppressants, which may raise the risk of osteoporosis.
The growing interest in osteoimmunology has highlighted the significance of inflammatory cytokines in bone homeostasis regulation. The discovery of shared pathophysiology pathways among skin conditions and osteoporosis could result in the development of a treatment modality that treats the former rather than the latter, or that is successful in both conditions.
Because of significant recent developments in pharmacological research in this field, a personalised therapeutic setting will allow the selection of the most suitable and effective treatment with the lowest amount of detrimental effects. High intensity topical corticosteroids, and immunosuppressants, are the current mainstays of treatment for most dermatologic diseases; however, long-term systemic immunosuppression may lead to significant bone morbidity when combined with chronic inflammation.
Recent developments in the study of skin disease aetiology have uncovered more cytokines and signalling cascades, allowing the investigation of innovative medicines that function particularly against a number of linked pro-inflammatory mediators.
Thus, the understanding of several developmental factors for osteoporosis, as well as ongoing investigations on the development of novel treatment modalities to address co-morbidities associated with osteoporosis will drive the overall market for osteoporosis drugs.
These factors are set to propel the overall market during the forecast period.
“Product Recalls and Adverse Effects Associated with Current Treatment Modalities”
Drug recall activities have proposed a negative impact upon the growth of the overall market for osteoporosis drugs. Approximately 3.8 lakh cartons of osteoporosis drug, due to the presence of an "unknown contaminant," produced by domestic pharmaceutical giant Sun Pharmaceutical Industries, were withdrawn in Puerto Rico and the US in March 2016. Sun Pharma Global Fze, a division of the Indian pharmaceutical giant, initiated the recall of these boxes of Alendronate Sodium tablets.
With such recall activities, the global value of the osteoporosis drugs market experiences a decline, thus necessitating novel drug launch activities. Moreover, with product recalls, companies face initial cost disadvantages.
Additionally, although Denosumab as a treatment modality for osteoporosis is typically well tolerated, there have been reports of a number of side effects, including musculoskeletal pain, hypersensitivity, dermatological responses, severe infections, and hypercholesterolemia. It is crucial to restore calcium levels before starting treatment since denosumab can cause hypocalcemia. Rare occurrences of atypical femoral fracture and jaw osteonecrosis linked to long-term denosumab use have also been recorded.
Side effects associated with treatment will reduce patient compliance, and often, treatment adoption rates.
These factors are thus set to restrain the overall growth of the osteoporosis drugs market over the forecasted years.
Why is the U.S. Market Booming?
“Growing Healthcare Investments and Rising Public Awareness”
The U.S. is set to account for around 37.5% share in the global market in 2023.
Governments around the world devote a large amount of their GDP to healthcare. Although healthcare spending varies greatly between nations, it has been one of the main areas of attention for all. In contrast to underdeveloped nations, healthcare spending is far higher in North American developed economies. The lower GDP per capita and hence decreased spending in emerging nations are mostly influenced by these factors. However, the cost of healthcare per person is also rising in developing nations, which helps the industry expand.
Moreover, rising prevalence of disease combined with the growing awareness regarding treatment will further propel the growth of the market in the country during the forecast period.
Will Germany Be a Lucrative Market for Osteoporosis Drugs?
“High Prevalence of Osteoporosis”
Germany is set to hold around 6.3% share of the global market in 2023.
With the presence of key manufacturers in the country, the market within Germany is set to gain traction in terms of sales revenue over the forecast period. Additionally, lifestyle disorders and the increasing prevalence of lifestyle associated diseases in Germany, are set to fuel market expansion over the projected years.
According to the International Osteoporosis Foundation (2021), in Germany, osteoporosis affects 6.6% of men and 22.6% of women who are 50 years or older. High prevalence of disease necessitates the development and adoption of treatment modalities for the management of osteoporosis within the European population, thus propelling market growth in Germany.
How is Japan Emerging as a Prominent Market?
“Development of Reimbursement Guidelines to Close Treatment Gap for Osteoporosis”
Japan is set to hold a market share of about 4.5% of the global market in 2023.
According to the Japanese osteoporosis treatment and prevention guidelines published in 2015, despite the enormous burden of fragility fractures, an approximated 80% of the 200,000 patients in Japan who experience a hip fracture each year as a result of osteoporosis do not receive treatment for the condition. The Japanese Fracture Liaison Services (FLS) reimbursement model has been revised as of April 2022 in order to close this substantial care gap. The reimbursement plan will significantly enhance post-fracture quality of care and secondary fracture management.
By including the examination for continual secondary fracture management, it will guarantee that individuals who have experienced a hip fracture will immediately be evaluated for osteoporosis and receive the necessary therapy, in accordance with FLS clinical standards with osteoporosis treatment strategies from pertinent academic societies.
Which Drug is Driving Demand within the Global Market?
“Treatment Efficacy and Adoption in Anticancer Therapies”
Bisphosphonates will hold around 43.6% of the total market in 2023. A class of medications known as bisphosphonates slow down bone resorption. Fractures of the spine and hip are less likely as a result. Although bone regeneration is a gradual process, many patients can measure an improvement in bone density after five years of therapy.
Furthermore, it has been demonstrated that bisphosphonates can treat a variety of solid tumours that affect the bones, including multiple myeloma, to lessen skeletal morbidity. To prevent skeletal problems and reduce bone pain, these medicines are being utilised more and more frequently in conjunction with anticancer therapies.
Which Distribution Channel Provides Traction to the Overall Market?
“Providing Solutions to Treatment Gaps”
Hospital pharmacies are expected to hold around 35.6% of the total share within the global market in 2023.
One of the most approachable health care providers and the acknowledged authorities on medications are pharmacists. There are various methods that pharmacists might help close the osteoporosis treatment gap. First off, pharmacists may help with public education on osteoporosis, screening, and diagnosis, as well as identifying those who may be at risk for the disease due to drugs. Additionally, pharmacists can aid in treatment uptake by assisting with agent selection and enhancing adherence. Finally, by detecting and advocating for the de-prescribing of drugs that may lead to an elevated fall risk, pharmacists conducting medication reviews can assist lower the risk of falls and associated fractures.
Thus, institutional sales with hospital pharmacies are far more beneficial for the treatment and management of osteoporosis, thus propelling the segment share within the global market.
To maintain market competition, the firms in the industry are implementing cooperative strategies. Manufacturers are spending money on R&D to release novel products on the market.
Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the osteoporosis drugs market, which are available in the full report.
Historical Data Available for
USD Million for Value
Key Countries Covered
Key Market Segments Covered
Key Companies Covered
Customization & Pricing
Available upon Request
The global market is currently valued at around US$ 13.0 Bn in 2022.
Sales of the market are set to witness growth at a CAGR of 3.5% and be valued at around US$ 18.9 Bn by 2033.
Demand for the global market increased at a 2.7% CAGR from 2016 to 2022.
The U.S., Germany, Japan, Australia, and India account for most demand within the market, currently holding around 56.7% market share.
The U.S. is set to account for around 37.5% share of the global market in 2023.
Europe is set to account for nearly one fourth share of the global market in 2023.
The Japan market is set to hold a share of about 4.5% in the global market in 2023.
China market is set to expand at a 4.7% CAGR over the forecast period, within the global market.
The Germany market is set to hold around 6.3% share in the global market in 2023.
India is set to expand at a 4.1% CAGR over the forecast period, within the global market.